Technical Analysis for CASBF - Cansino Biologics Inc

Grade Last Price % Change Price Change
grade D 24.5 -0.04% -0.0100
CASBF closed down 0.04 percent on Wednesday, June 3, 2020, on 10 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical CASBF trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -0.04%
Stochastic Buy Signal Bullish -0.04%
Calm After Storm Range Contraction -0.04%
Narrow Range Bar Range Contraction -0.04%
NR7 Range Contraction -0.04%
Older signals for CASBF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

CanSino Biologics Inc. focuses on developing, manufacturing, and commercializing vaccines in the People's Republic of China. Its vaccines include Ad5-EBOV, an Ebola virus vaccine; MCV4 vaccine that is Phase III clinical trial for the prevention of N. meningitides; MCV2 vaccine for treating N. meningitides; DTcP vaccine is for infants, which is in Phase I clinical trails; and DTcP Booster vaccine that is in Phase I clinical trial for addresses the weaker protection preventing pertussis after primary vaccination. The company's product candidates also comprise Tdcp Adolescent and Adult vaccine, which is in Phase I clinical trial for treating pertussis; TB Booster, a 5 adenovirus-based tuberculosis vaccine; PBPV, a serotype-independent protein-based pneumococcal vaccine, which is in Phase I clinical trial; and PCV13i, a pneumococcal conjugate vaccine that is in Phase I clinical trial. It is also developing various preclinical stage products, including CSB016 for treating shingles; CSB014, a combination vaccine; CSB105 to treat meningitis; CSB107 for polio; CSB012 for treating adenovirus; and CSB013 for ZIKA virus. The company has a strategic partnership with Ocugen, Inc. for the development of gene therapy product candidates; and research and development collaboration agreement with BIRD-C Gmbh to explore bacterial ghosts (BGs) as standalone adjuvant to its vaccines, as well as bacterial antigen expressing directly in E. coli carrier BGs to produce new vaccines. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.
Medicine Medical Specialties Gene Therapy Vaccination Vaccines Vaccine Ebola Vaccine Meningitis Pertussis Tb

Is CASBF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 59.99
52 Week Low 16.08
Average Volume 8,632
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 24.9870
10-Day Moving Average 25.6160
Average True Range 3.9516
ADX 45.36
+DI 47.3078
-DI 19.2048
Chandelier Exit (Long, 3 ATRs ) 48.1352
Chandelier Exit (Short, 3 ATRs ) 27.9348
Upper Bollinger Band 33.6887
Lower Bollinger Band 16.2853
Percent B (%b) 0.47
BandWidth 69.6498
MACD Line 1.3269
MACD Signal Line 1.9307
MACD Histogram -0.6038
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.9400
Resistance 3 (R3) 25.7800 25.1400 25.7000
Resistance 2 (R2) 25.1400 24.7733 25.2200 25.6199
Resistance 1 (R1) 24.8200 24.5467 24.9800 24.9800 25.5400
Pivot Point 24.1800 24.1800 24.2600 24.2600 24.1800
Support 1 (S1) 23.8600 23.8133 24.0200 24.0200 23.4600
Support 2 (S2) 23.2200 23.5867 23.3000 23.3801
Support 3 (S3) 22.9000 23.2200 23.3000
Support 4 (S4) 23.0600